Altimeo Asset Management v. Jumei International Holding Limited, 3:20-cv-02751

Background

Jumei International, a Cayman-listed e‑commerce holding company, was majority-controlled by CEO/Chairman Leo Ou Chen, who launched a $2.00-per-share tender offer in January 2020 to take the company private via a Cayman short‑form merger.
Jumei’s independent Special Committee retained Houlihan Lokey, which issued a fairness opinion concluding Chen’s offer was "fair." Houlihan relied on management‑provided assumptions, including that Jiedian (a power‑bank business) could not obtain third‑party financing and that non‑Jiedian operations would be wound down.
Lead plaintiff Altimeo alleged the fairness opinion and related filings were false/misleading because (a) Jiedian was a market leader with financing opportunities and strong prospects, and (b) Jumei’s e‑commerce/Shuabao businesses were not being wound down; Altimeo also challenged statements that appraisal (dissenters’) rights were unavailable under Cayman law.
The Special Committee approved the deal; Chen obtained sufficient tendered shares and completed the short‑form merger; stockholders received $2 per share and the company was delisted.
The district court granted Jumei’s motions to dismiss the amended complaints, holding Altimeo failed to plead (1) loss causation for its Section 10(b) and Section 14(e) claims and (2) scienter for Section 10(b); the court dismissed with leave to amend (30 days).

Issues

Issue	Plaintiff's Argument	Defendant's Argument	Held
Falsity of fairness opinion and inputs	Houlihan’s fairness opinion was based on false management assumptions (Jiedian financing constraints; winding down other businesses), rendering the opinion and Recommendation Statement misleading.	Houlihan explicitly relied on management and due diligence; many allegedly contrary facts were public; plaintiffs’ confidential witness allegations lack particularity to show objective falsity.	Court: Plaintiffs likely failed to plead objective falsity for non‑Jiedian winding‑down claims; Jiedian financing allegations closer but not necessary to decide given dismissal on scienter and loss causation.
Scienter under §10(b)	Directors and Chen acted intentionally or with deliberate recklessness in endorsing a knowingly undervalued buyout; Special Committee members had access and motive.	Allegations rely on motive/opportunity, group pleading, or management access without particularized facts; Chen was an adverse buyer and not the maker of the Recommendation Statement.	Court: Failed to plead a strong inference of scienter for Special Committee members or the board; Chen’s state of mind not imputable to Jumei for the challenged statements. Dismissed §10(b) claims.
Negligence under §14(e)	Even if scienter is lacking, defendants were negligent in failing to investigate financing and valuation assumptions and in omitting appraisal‑rights ambiguity.	The Special Committee conducted a robust review with advisors; plaintiffs do not plead particularized facts showing lack of reasonable prudence for each defendant.	Court: Close question; did not decide definitively but noted plaintiffs face pleading hurdles; dismissed §14(e) claims on loss causation grounds.
Loss causation / Appraisal‑rights theory	Misstatements prevented shareholders from being fully informed, causing them to sell at undervalued price; stating appraisal rights were unavailable suppressed arbitrage that would have raised price.	Plaintiffs received a ~15% premium over market; alleged "true value" is speculative and undermined by lack of competing bidders and public market information; appraisal‑rights theory is highly attenuated.	Court: Plaintiffs failed to plead loss causation for both §10(b) and §14(e) claims (including appraisal‑rights allegations); dismissal warranted.

Key Cases Cited

Ashcroft v. Iqbal, 556 U.S. 662 (2009) (pleading must state a plausible claim; courts accept well‑pleaded facts but not legal conclusions)
Bell Atl. Corp. v. Twombly, 550 U.S. 544 (2007) (plausibility standard for pleading)
Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (2007) (PSLRA requires that an inference of scienter be ‘‘cogent and at least as compelling as any opposing inference’’)
Endologix, Inc. v. Nguyen, 962 F.3d 405 (9th Cir.) (explaining scienter pleading and comparing competing inferences under PSLRA)
City of Dearborn Heights Act 345 Police & Fire Ret. Sys. v. Align Tech., Inc., 856 F.3d 605 (9th Cir. 2017) (standards for pleading falsity of opinion statements)
Zucco Partners, LLC v. Digimarc Corp., 552 F.3d 981 (9th Cir. 2009) (PSLRA particularity and scienter analysis)
Halliburton Co. v. Erica P. John Fund, Inc., 573 U.S. 258 (2014) (presumption that market price reflects publicly available material information)
Omnicare, Inc. v. Laborers Dist. Council Constr. Indus. Pension Fund, 575 U.S. 175 (2015) (standards for falsity of opinion statements)
In re NVIDIA Corp. Sec. Litig., 768 F.3d 1046 (9th Cir.) (holistic scienter analysis and stepwise inquiry)
In re Rigel Pharm., Inc. Sec. Litig., 697 F.3d 869 (9th Cir.) (access to internal data does not alone establish scienter)
Varjabedian v. Emulex Corp., 888 F.3d 399 (9th Cir.) (Section 14(e) negligent‑misstatement standard contrasted with Rule 10b‑5 scienter requirement)
In re Ocera Therapeutics, Inc. Sec. Litig., [citation="806 F. App'x 603"] (9th Cir.) (loss causation dismissal where alleged "true value" was speculative and market/buyer dynamics undercut plaintiff’s theory)